Compare OGI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGI | QNCX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3M | 167.0M |
| IPO Year | 2015 | 2019 |
| Metric | OGI | QNCX |
|---|---|---|
| Price | $1.44 | $0.12 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 749.9K | ★ 123.6M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.93 | N/A |
| Revenue Next Year | $8.00 | N/A |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $0.13 |
| 52 Week High | $2.24 | $4.55 |
| Indicator | OGI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 27.25 |
| Support Level | $1.29 | N/A |
| Resistance Level | $1.46 | $0.98 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 48.53 | 2.22 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.